- PR Newswire•yesterday
LEXINGTON, Mass., April 27, 2017 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its first quarter 2017 financial results before the market opens on Thursday, May 4, 2017. Agenus executives will host a conference call at 11:00 a.m. ET the same day. The call will also be webcast and will be accessible from the company's website at www.agenusbio.com/webcast.
- American City Business Journals•4 days ago
The World Health Organization said Monday that the world’s first malaria vaccine, which features a key component made by Lexington biotech Agenus, will be available in parts of Africa beginning next year. The WHO’s African regional office said that Ghana, Kenya and Malawi would participate in a pilot program for the injectable vaccine, which was developed by U.K. drug giant GlaxoSmithKline (GSK) with funding from the Bill & Melinda Gates Foundation. The vaccine contains a so-called adjuvant made by Agenus (AGEN), which is designed to boost the body’s immune response.
- Zacks•4 days ago
Agenus Inc. (AGEN) is expected to report first-quarter 2017 results later this month or early next month.
AGEN : Summary for Agenus Inc. - Yahoo Finance
Agenus Inc. (AGEN)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||3.57 x 2100|
|Ask||3.58 x 3300|
|Day's Range||3.52 - 3.70|
|52 Week Range||2.97 - 7.49|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.45|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|